NCT06247657View on ClinicalTrials.gov

A Phase I Study to Assess the Safety and Tolerability of BL0006 for Patients With Advanced Solid Tumours

PHASE1RecruitingINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

January 3, 2024

Primary Completion Date

October 31, 2024

Study Completion Date

May 31, 2025

Conditions
Advanced Solid Tumor
Interventions
DRUG

BL0006

Patients will be administered BL0006 via intravenous infusion at the corresponding dose level on days 1 and 8 of a 21-days treatment cycle.

Trial Locations (2)

130000

NOT_YET_RECRUITING

The First Hospital of Jilin University, Changchun

200032

RECRUITING

Zhongshan Hospital, Fudan University, Shanghai

All Listed Sponsors
lead

Shanghai Best-Link Bioscience, LLC

INDUSTRY